Sanofi Consumer Healthcare India Limited
Sanofi Consumer Healthcare India Limited was incorporated on May 10, 2023. Pursuant to the Scheme becoming effective, the Consumer Healthcare Division (CHC) business of Sanofi India Limited (SIL) got demerged into the Company as a going concern through the Scheme of Arrangement and became effective from June 1, 2024. In terms of the said Scheme, the Company allotted 23,030,622 Equity Shares to the eligible…
What Sanofi files
- Others62
- Important15
- Updates9
- Board Meeting9
- Dividend/Bonus5
- Investor Meet1
Sanofi Consumer Healthcare India reported strong Q2 performance with revenue up 7% YoY to ₹235.7 Cr and PBT up 16% to ₹91.9 Cr. H1 revenue grew 18% to ₹464.9 Cr, PBT up 25% to ₹182.6 Cr. Domestic sales climbed 12%, boosted by product relaunches.
Sanofi Consumer Healthcare announced its Annual General Meeting. A final dividend will be distributed to shareholders on record. Book closure period set to process these dividend payments.
Sanofi Consumer Healthcare India's Board approved Q1'26 financial results. Revenue surged 33% YoY to ₹229.2 Cr, with Net Profit up 36% to ₹67.8 Cr. Domestic sales grew 15.5% (relaunches), while exports soared 144%, reflecting disciplined execution.
Sanofi Consumer Healthcare reports strong Q4'25 results: Revenue up 47% to ₹251 Cr, Net Profit up 50% to ₹66.5 Cr. FY revenue at ₹878.4 Cr (+21%), Net Profit ₹240.1 Cr (+33%). Performance driven by product relaunches and export growth. A ₹75 dividend per share was declared.
Sanofi Consumer Healthcare reports Q3 revenue of ₹233.9 Cr (+46% YoY) and profit of ₹62.9 Cr (+40% YoY). Nine-month revenue grew 13%, profit 27%. All voluntarily recalled products have successfully re-established market presence. Ownership shifted: Opal JVco is now the ultimate parent.